BioWorld

April 1, 2008

Tekmira and Provita Merge to Form RNAi Powerhouse

Canadian firms Tekmira Pharmaceuticals Corp. and Protiva Biotherapeutics Inc. are merging to become a stronger international player in the RNA interference therapeutics space. (BioWorld Today) Read More

Merck, Schering Knocked by Vytorin Data, Physician Panel

Even in Hindsight, No Problems with Co-Stimulation in Rodents

$10M Deal: Acusphere Licenses HDDS, Compound to Cephalon

Transave Garners $35M to Aid Pipeline Push in Lung Diseases

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...